Cancer Immunology, Immunotherapy

, Volume 56, Issue 7, pp 1097–1105

Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110

  • Hyung L. Kim
  • Xiaolei Sun
  • John R. Subjeck
  • Xiang-Yang Wang
Original Article

DOI: 10.1007/s00262-006-0258-z

Cite this article as:
Kim, H.L., Sun, X., Subjeck, J.R. et al. Cancer Immunol Immunother (2007) 56: 1097. doi:10.1007/s00262-006-0258-z

Abstract

Carbonic anhydrase IX (CA9) is a renal cell carcinoma (RCC)-specific tumor protein that is targeted using heat shock protein 110 (hsp110). The chaperoning ability of hsp110 can be utilized to form a complex with CA9 (hsp110 + CA9) in vitro, which can be administered as a highly concentrated tumor vaccine. In a tumor prevention model, hsp110 + CA9 prevented the growth of RENCA tumors in BALB/c mice, and produced IFN-γ response measured using ELISPOT and an antibody response measured using ELISA. To test a second vaccine strategy, hsp110 complexed to a previously described CA9 peptide prevented tumor growth and produced a very weak IFN-γ response, but no antibody response. A plasmid vector containing grp170, a member of the hsp110 family, linked to CA9 did not produce an antitumor response and produced no IFN-γ response or antibodies. In a model of metastatic RCC, RENCA cells were injected intradermally prior to vaccination. Hsp110 + CA9 decreased tumor growth compared to control vaccinations. These studies suggest that recombinant hsp110 complexed to CA9 should be evaluated for treatment of RCC.

Keywords

Renal cell carcinomaCarbonic anhydrase IXHeat shock proteinTumor vaccineRENCAHeat shock protein 110

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Hyung L. Kim
    • 1
  • Xiaolei Sun
    • 1
  • John R. Subjeck
    • 2
  • Xiang-Yang Wang
    • 1
    • 2
  1. 1.Department of Urologic OncologyRoswell Park Cancer InstituteBuffaloUSA
  2. 2.Department of Cell Stress BiologyRoswell Park Cancer InstituteBuffaloUSA